---
layout: default
title: Abemaciclib
parent: 僅模型預測 (L5)
nav_order: 14
evidence_level: L5
indication_count: 0
---

# Abemaciclib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# ABEMACICLIB: Drug Repurposing Evaluation Report

## One-Sentence Summary

Abemaciclib is a selective CDK4/6 inhibitor, widely approved internationally for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
The TxGNN model **did not generate any predicted new indications** for this drug in the current analysis run.
As a result, this report serves as a **baseline data status assessment** rather than a full repurposing evaluation.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not recorded in this evidence pack (internationally approved for HR+/HER2− breast cancer) |
| Predicted New Indication | **None** — TxGNN returned no predicted indications |
| TxGNN Prediction Score | N/A |
| Evidence Level | **L5** (No predictions, no supporting studies in pack) |
| Taiwan Market Status | ❌ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No new indication was predicted by TxGNN in this analysis cycle. Therefore, a mechanistic plausibility assessment cannot be performed at this time.

For reference, Abemaciclib is a selective, orally bioavailable inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By blocking CDK4/6, it prevents phosphorylation of the retinoblastoma protein (Rb), thereby arresting the cell cycle at the G1-to-S phase transition and inhibiting tumour cell proliferation. This mechanism has been validated in HR+/HER2− breast cancer and is being explored in other CDK4/6-dependent malignancies internationally. However, the evidence pack's MOA field was not populated, and this description is based on established pharmacological knowledge.

Should TxGNN generate candidate indications in future runs, the CDK4/6 inhibition mechanism provides a rational basis for exploring repurposing in tumour types with Rb pathway dependency (e.g., certain lung cancers, liposarcomas, mantle cell lymphoma).

---

## Clinical Trial Evidence

No predicted indication was returned by the TxGNN model, so no indication-specific clinical trials are presented.

---

## Literature Evidence

No predicted indication was returned by the TxGNN model, so no indication-specific literature is presented.

---

## Taiwan Market Information

Abemaciclib currently holds **no TFDA marketing authorizations** in Taiwan (market status: 未上市). No license records are available.

---

## Cytotoxicity

Abemaciclib is an **antineoplastic agent** (CDK4/6 inhibitor, classified as targeted therapy). The following cytotoxicity profile is provided based on established pharmacological knowledge, as the evidence pack did not contain detailed toxicity data.

| Item | Content |
|------|------|
| Cytotoxicity Classification | **Targeted therapy** (selective CDK4/6 inhibitor; not a conventional cytotoxic agent) |
| Myelosuppression Risk | **Moderate to High** — Neutropenia is a common adverse effect of CDK4/6 inhibitors; dose adjustments may be required |
| Emetogenicity Classification | **Low to Moderate** — Diarrhoea is more clinically significant than nausea/vomiting for this drug |
| Monitoring Items | CBC with differential (neutrophils especially), liver function tests (ALT/AST/bilirubin), serum creatinine, signs of venous thromboembolism, signs of interstitial lung disease |
| Handling Protection | Standard oral targeted therapy handling; does not require the full cytotoxic drug handling precautions applicable to conventional chemotherapy |

---

## Safety Considerations

The evidence pack did not contain populated safety data (warnings, contraindications, or drug-drug interactions were not available from TFDA or DDI queries).

> Please refer to the package insert for safety information. Internationally, key safety concerns for abemaciclib include diarrhoea, neutropenia, hepatotoxicity, venous thromboembolism, and interstitial lung disease/pneumonitis.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN model did not return any predicted new indications for Abemaciclib in this analysis run. Without a candidate indication, no repurposing evaluation can proceed. Additionally, the drug is not currently marketed in Taiwan, and multiple data gaps (MOA, TFDA labelling/warnings, contraindications) remain unresolved.

**To proceed, the following is needed:**
- **Re-run TxGNN prediction** with updated knowledge graph data to determine if new indications emerge
- **Populate MOA data** via DrugBank API (Data Gap DG002, severity: High)
- **Obtain TFDA package insert** warnings and contraindications if/when the drug gains marketing authorization (Data Gap DG001, severity: Blocking)
- **Monitor Taiwan regulatory status** — Abemaciclib is marketed in many countries (US: Verzenio; EU: Verzenios); Taiwan approval may be forthcoming
- **If a predicted indication is generated in future**, re-initiate the evaluation pipeline with a complete evidence pack
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

